Sept 27, 2021 Pfizer Inc. (NYSE: PFE) today announced the start of the Phase 2/3 EPIC-PEP study to evaluate the investigational novel oral antiviral candidate PF-07321332
Nov 5, 2021 Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID , significantly reduced hospitalization and death
It took only 39 days to recruit enough people, randomize them, treat them, wait 28 days, collect the data, combine data from 183 recruiting centers and evaluate the results to present data to the FDA?
Are there scientist questioning Pfizer credibility?
